Theravance Biopharma, Inc. (TBPH) — 10-Q Filings
All 10-Q filings from Theravance Biopharma, Inc.. Browse 7 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (7)
- 10-Q Filing — May 7, 2026
-
Theravance Biopharma Swings to Profit on Milestone Gain, YUPELRI China Approval
— Nov 12, 2025 Risk: medium
Theravance Biopharma, Inc. (TBPH) reported a significant turnaround, achieving a net income of $44.87 million for the nine months ended September 30, 2025, a su -
Theravance Biopharma Swings to Profit on $75M Royalty Gain, China Approval
— Aug 13, 2025 Risk: medium
Theravance Biopharma, Inc. (TBPH) reported a significant financial turnaround for the three and six months ended June 30, 2025. The company achieved a net incom -
Theravance Biopharma Files Q1 2025 10-Q
— May 12, 2025 Risk: low
Theravance Biopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business oper -
Theravance Biopharma Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
Theravance Biopharma, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the thi -
Theravance Biopharma Q2 Revenue Down, Net Loss Persists
— Aug 8, 2024 Risk: medium
Theravance Biopharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total revenue of $48.7 million for the quarter, a decrease f -
Theravance Biopharma, Inc. Files 10-Q for Period Ending March 31, 2024
— May 15, 2024 Risk: low
Theravance Biopharma, Inc. (TBPH) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Theravance Biopharma reported revenue of $48.28 million for the
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX